SCHEMBL1969965

SCHEMBL1969965

O=S(=O)(OS(=O)(=O)c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.59
CYP3A4 P08684 1/20 0.59
MAPK1 P28482 1/20 0.59
CA1 P00915 5/20 0.54
CA2 P00918 5/20 0.54
CA9 Q16790 4/20 0.54
CA12 O43570 3/20 0.54
CA3 P07451 3/20 0.54
CA4 P22748 3/20 0.54
CA6 P23280 3/20 0.54
CA5A P35218 3/20 0.54
CA7 P43166 3/20 0.54
CA13 Q8N1Q1 3/20 0.54
CA14 Q9ULX7 3/20 0.54
CA5B Q9Y2D0 3/20 0.54
TDP1 Q9NUW8 1/20 0.52
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
MMP2 P08253 2/20 0.48
MMP1 P03956 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1759744 0.91 TDP1 (0.66) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL5314186 0.89 BCHE (0.54) ALDH1A1CYP3A4MAPK1CA1CA2
Biphenyl SCHEMBL3116344 0.87 TDP1 (0.56) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL28864044 0.84 ALDH1A1 (0.59) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL7850856 0.82 ALDH1A1 (0.56) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL5165470 0.81 TDP1 (0.59) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL9418416 0.81 TDP1 (0.46) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL28864047 0.80 ALDH1A1 (0.54) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL197599 0.80 ALDH1A1 (0.54) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL1985748 0.80 ALDH1A1 (0.54) ALDH1A1CYP3A4MAPK1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865932-B Preparation method of benzothiophene sulfone compound with medicinal and fluorescent activity BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY (CN) 2026-05-26 CN claimed
CN-117865932-A Preparation method of benzothiophene sulfone compound with medicinal and fluorescent activity 北京化工大学 2024-04-12 CN claimed
US-4115058-A BLEACHES, DETERGENTS FMC CORPORATION (US) 1978-09-19 US claimed
EP-2334640-B1 METHODS FOR PRODUCING PARICALCITOL AZAD PHARMACEUTICAL INGREDIENTS AG (CH) 2015-12-23 EP disclosed
US-9212136-B2 Methods for producing paricalcitol AZAD PHARMACEUTICALS INGREDIENTS AG (CH) 2015-12-15 US disclosed
EP-1274681-B1 PROCESS FOR PRODUCING AMIDE COMPOUND MITSUBISHI CHEM CORP (JP) 2011-08-17 EP disclosed
US-20110184199-A1 Methods For Producing Paricalcitol AZAD PHARMA AG (CH) 2011-07-28 US disclosed
EP-2334640-A2 METHODS FOR PRODUCING PARICALCITOL Azad Pharmaceutical Ingredients AG (CH) 2011-06-22 EP disclosed
WO-2010009879-A2 METHODS FOR PRODUCING PARICALCITOL AZAD PHARMACEUTICAL INGREDIENTS AG (CH) 2010-01-28 WO disclosed
EP-1274681-A1 PROCESS FOR PRODUCING AMIDE COMPOUND MITSUBISHI CHEMICAL CORPORATION (JP) 2003-01-15 EP disclosed
US-6489474-B1 A PROCESS FOR PRODUCING AN AMIDE COMPOUND BY SUBJECTING AN OXIME COMPOUND TO BECKMANN REARRANGEMENT IN A LIQUID PHASE, WHEREIN THE REACTION IS CARRIED OUT IN THE PRESENCE OF A NON-FLUORINE-CONTAINING SULFONIC ANHYDRIDE AND AN MITSUBISHI CHEMICAL CORPORATION (JP) 2002-12-03 US disclosed
WO-2001081302-A1 PROCESS FOR PRODUCING AMIDE COMPOUND MITSUBISHI CHEMICAL CORPORATION (JP) 2001-11-01 WO disclosed
US-4689412-A ANHYDRIDES OF SULFONIC ACIDS OR SULFURIC ACID HALF ESTERS, CATALYSTS HULS AKTIENGESELLSCHAFT (DE) 1987-08-25 US disclosed
US-4115058-A BLEACHES, DETERGENTS FMC CORPORATION (US) 1978-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110184199-A1 Methods For Producing Paricalcitol CYP2R1, PTH1R, CYP24A1 ALDH1A1 3875/4885CYP3A4 1025/4885MAPK1 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.